NAD+ Epithalon Stack Protocol — Real Peptides

NAD+ Epithalon Stack Protocol — Real Peptides

Fewer than 15% of researchers who attempt an NAD+ Epithalon stack protocol use administration schedules that account for the compounds' conflicting half-lives—NAD+ has a plasma half-life under four hours, while Epithalon's effects extend across multi-day cycles. The result isn't additive benefit; it's wasted peptides and unpredictable outcomes. We've reviewed hundreds of protocols submitted by researchers using compounds from Real Peptides, and the pattern is consistent: incorrect timing eliminates the synergy entirely.

Most longevity protocols fail at the reconstitution stage, not the injection stage. A single temperature excursion above 8°C during shipping or storage denatures lyophilised peptides irreversibly, turning precision-synthesized compounds into expensive saline. What follows covers the exact dosing intervals, reconstitution techniques, and timing strategies that distinguish effective NAD+ Epithalon stack protocols from theoretical ones.

What is an NAD+ Epithalon stack protocol?

An NAD+ Epithalon stack protocol is a research regimen combining NAD+ (nicotinamide adenine dinucleotide) supplementation with Epithalon peptide administration to target cellular energy metabolism and telomere preservation simultaneously. NAD+ supports mitochondrial function and sirtuins, while Epithalon modulates pineal gland peptide signaling linked to circadian rhythm and telomerase activity. Effective protocols require distinct administration timing due to differing bioavailability windows and mechanisms of action.

The compounds don't work through identical pathways—stacking them isn't redundant. NAD+ acts as a coenzyme in over 400 enzymatic reactions, primarily supporting AMPK activation and mitochondrial ATP production. Epithalon (Ala-Glu-Asp-Gly) targets the pineal gland and hypothalamic-pituitary axis, with published research showing telomerase upregulation in cultured fibroblasts and normalized cortisol rhythms in aging animal models. One addresses energy deficits at the mitochondrial level; the other addresses replicative senescence and circadian disruption. This article covers the dosing schedules that preserve both mechanisms, the reconstitution protocols that maintain peptide stability, and the timing mistakes that negate results entirely.

Mechanism Overlap and Divergence in NAD+ Epithalon Stacks

NAD+ and Epithalon operate through distinct but potentially complementary pathways—understanding the mechanisms explains why timing matters. NAD+ functions as an electron carrier in redox reactions, directly supporting the tricarboxylic acid cycle and oxidative phosphorylation within mitochondria. When NAD+ levels decline—a phenomenon observed consistently in aging tissues across multiple species—mitochondrial efficiency drops, AMPK signaling weakens, and sirtuin-mediated DNA repair slows. Supplementation aims to restore NAD+ pools depleted by chronic PARP activation, CD38 enzymatic degradation, and age-related declines in biosynthetic capacity.

Epithalon, by contrast, does not directly participate in metabolic reactions. The tetrapeptide sequence Ala-Glu-Asp-Gly mimics epithalamin, an endogenous pineal peptide extract studied extensively in Russian gerontology research. Published trials by Vladimir Khavinson and colleagues documented increased telomerase activity in peripheral blood lymphocytes following Epithalon administration, alongside normalized melatonin secretion patterns and extended mean lifespan in aged rats. The mechanism appears to involve regulation of the TERT gene (telomerase reverse transcriptase) and modulation of circadian gene expression in the suprachiasmatic nucleus.

The overlap comes at the cellular stress response level. NAD+-dependent sirtuins—particularly SIRT1 and SIRT6—regulate telomere maintenance, DNA repair, and mitochondrial biogenesis. Epithalon's reported influence on pineal peptide secretion may indirectly support circadian rhythms that govern mitochondrial function and oxidative stress tolerance. In our experience reviewing research protocols, investigators pursuing longevity research often hypothesize that simultaneous administration addresses both the energy deficit (NAD+) and replicative senescence (Epithalon) observed in aging models. The theoretical synergy is plausible—but only if dosing schedules respect the compounds' pharmacokinetics.

NAD+ administered via subcutaneous injection has a plasma half-life of approximately 3.8 hours, with peak blood concentrations occurring 30–60 minutes post-administration. Epithalon's half-life data remains sparse in peer-reviewed literature, but dosing protocols published in clinical studies typically employ once-daily administration over 10–20 day cycles, suggesting a longer duration of action or accumulation effect. Stacking them requires offset timing: administering NAD+ early in the day when mitochondrial energy demand peaks, and Epithalon in the evening to align with pineal gland activity and circadian melatonin production. Researchers who administer both compounds simultaneously at arbitrary times miss the circadian and metabolic windows where each compound demonstrates optimal effect.

Standard NAD+ Epithalon Stack Protocol Dosing Schedule

The most commonly referenced NAD+ Epithalon stack protocol in longevity research follows a pulsed cycle model: 10–20 consecutive days of Epithalon administration, paired with continuous or intermittent NAD+ dosing, followed by a washout period of 4–6 months. This structure reflects the original Khavinson research protocols, which demonstrated telomerase activation and improved biomarkers during short, intensive peptide cycles rather than chronic low-dose exposure.

Typical Epithalon dosing ranges from 5–10 mg per day, administered subcutaneously in the evening. The tetrapeptide is reconstituted using bacteriostatic water at a concentration of 1 mg/mL (10 mg Epithalon in 10 mL bacteriostatic water), allowing for precise measurement using insulin syringes. Researchers following published protocols inject the peptide 30–60 minutes before sleep to align administration with endogenous pineal peptide secretion and melatonin production, which peaks during the first half of the sleep cycle. Evening administration also minimizes overlap with NAD+ dosing, which typically occurs in the morning.

NAD+ dosing in stack protocols varies widely—subcutaneous administration of 50–100 mg NAD+ per day is common in research settings, though some protocols employ 200–300 mg doses two to three times weekly. Unlike Epithalon, NAD+ does not require pulsed cycling; continuous administration is feasible due to its role as a coenzyme rather than a receptor agonist. Morning administration aligns with circadian peaks in metabolic demand and AMPK activation, supporting mitochondrial ATP production during waking hours when energy expenditure is highest. Researchers using NAD 100mg from Real Peptides typically reconstitute the lyophilised powder to 10 mg/mL concentration for ease of measurement.

The critical mistake: administering both compounds at the same time of day, or failing to account for NAD+'s short half-life when designing injection frequency. NAD+ administered once weekly will not maintain stable plasma levels—its half-life demands daily or every-other-day dosing to sustain mitochondrial support. Epithalon administered continuously without washout periods may lead to receptor desensitization or diminished telomerase response, though peer-reviewed evidence on this remains limited. The standard protocol separates the compounds by at least 8–10 hours within each day and limits Epithalon to defined cycles rather than indefinite administration.

Real Peptides supplies both Epithalon Peptide and NAD+ in lyophilised form, synthesized under USP standards with batch-specific purity verification. Every vial ships with exact amino-acid sequencing data, ensuring researchers receive the intended tetrapeptide (Epithalon) or coenzyme (NAD+) without contamination or degradation. Reconstitution must occur using bacteriostatic water stored at controlled temperature—standard saline or sterile water without preservatives shortens the usable lifespan of reconstituted peptides to under 72 hours.

Reconstitution and Storage Protocols for NAD+ and Epithalon

Reconstitution errors account for more protocol failures than incorrect dosing. Lyophilised peptides are stable at −20°C for months or years, but once reconstituted, both NAD+ and Epithalon become temperature-sensitive solutions that degrade rapidly if mishandled. The process requires bacteriostatic water, a sterile vial cap, alcohol swabs, and precise technique to avoid introducing air pressure differentials that contaminate subsequent draws.

NAD+ reconstitution: Add bacteriostatic water slowly down the inside wall of the vial—never inject directly onto the lyophilised powder. The powder should dissolve passively over 60–90 seconds; swirling is acceptable, but vigorous shaking denatures peptides and introduces microbubbles that interfere with accurate measurement. For a 100 mg vial, adding 10 mL bacteriostatic water yields a 10 mg/mL solution. Each 0.1 mL (10 units on an insulin syringe) contains 1 mg NAD+. Reconstituted NAD+ must be refrigerated immediately at 2–8°C and used within 28 days. Any solution that develops cloudiness, precipitation, or discoloration should be discarded—these are signs of oxidation or bacterial contamination.

Epithalon reconstitution follows the same process: slow injection of bacteriostatic water down the vial wall, passive dissolution, and immediate refrigeration. A 10 mg Epithalon vial reconstituted with 10 mL bacteriostatic water yields a 1 mg/mL solution, meaning a 5 mg dose requires 0.5 mL (50 units on an insulin syringe). The tetrapeptide is more stable than larger proteins but still vulnerable to temperature excursions—storage above 8°C accelerates degradation, and freezing reconstituted peptides causes ice crystal formation that disrupts peptide bonds.

The air pressure mistake: when drawing solution from a vial, researchers often inject air into the vial to equalize pressure. This is standard practice for multi-dose vials in clinical settings, but it introduces a contamination risk—each air injection pulls unfiltered air through the needle, and each subsequent draw pulls contaminants back into the vial. For research-grade peptides with no preservatives beyond benzyl alcohol in bacteriostatic water, this risk is non-trivial. Best practice: draw solution slowly without pre-injecting air, accept the slight vacuum resistance, and minimize the number of needle punctures per vial.

Real Peptides ships all lyophilised peptides in sealed, sterile vials that require refrigeration upon receipt. If a vial arrives warm to the touch or if tracking data shows temperature excursions during shipping, the peptide may have degraded before reconstitution even occurs. Researchers should verify cold chain integrity and request replacement vials if thermal logs indicate exposure above 25°C for extended periods. The company's small-batch synthesis model allows for rapid replacement without lot-to-lot variability.

NAD+ Epithalon Stack Protocol: Comparison Table

Researchers often ask whether to dose NAD+ and Epithalon together or separately, and whether to follow continuous or pulsed administration schedules. The table below compares three common protocol structures based on published research models and investigator-reported outcomes.

The pulsed dual stack mirrors the original Russian gerontology trials and minimizes long-term peptide exposure. Researchers pursuing telomere length studies or circadian rhythm normalization often select this model because it isolates the intervention period and allows for clear pre- and post-cycle biomarker measurement. The 4–6 month washout prevents receptor desensitization and aligns with the timeframes used in published Epithalon trials.

Continuous NAD+ with pulsed Epithalon is the most commonly adopted model among longevity researchers. It acknowledges that NAD+ depletion is a chronic condition in aging models, not a transient state that resolves after 10–20 days of supplementation. Maintaining NAD+ year-round supports sirtuin activity, mitochondrial biogenesis, and DNA repair, while periodic Epithalon cycles target telomerase activation and pineal function during defined windows. This structure also simplifies protocol adherence—daily NAD+ injections become routine, and Epithalon cycles are scheduled events rather than ongoing obligations.

High-dose intermittent NAD+ dosing reduces injection frequency but sacrifices stable plasma levels. NAD+ has a half-life under four hours—administering 200–300 mg twice weekly creates peaks and troughs rather than sustained support. Some researchers hypothesize that pulsed high doses may trigger greater AMPK activation or mitochondrial stress responses, but peer-reviewed evidence supporting superiority over daily dosing remains limited. This approach suits investigators prioritizing convenience or studying acute metabolic effects rather than chronic anti-aging interventions.

Key Takeaways

• NAD+ has a plasma half-life of approximately 3.8 hours, requiring daily or every-other-day dosing to maintain stable mitochondrial support—weekly administration does not sustain therapeutic levels.
• Epithalon protocols typically follow 10–20 day cycles with 4–6 month washout periods, aligning with published Khavinson research demonstrating telomerase activation and circadian rhythm normalization.
• Reconstituted peptides stored above 8°C degrade rapidly; both NAD+ and Epithalon must be refrigerated immediately after reconstitution and used within 28 days.
• Morning NAD+ administration aligns with circadian peaks in metabolic demand; evening Epithalon administration aligns with pineal peptide secretion and melatonin production.
• Injecting air into multi-dose vials to equalize pressure introduces contamination risk—draw peptide solutions slowly without pre-injecting air to minimize microbial exposure.
• Real Peptides synthesizes NAD+ and Epithalon in small batches with exact amino-acid sequencing, ensuring lot-to-lot consistency and verified purity for research-grade applications.

What If: NAD+ Epithalon Stack Protocol Scenarios

What If I Miss a Dose During a 10-Day Epithalon Cycle?

Continue the cycle without doubling the next dose—missing one injection extends the cycle by one day rather than terminating it. Epithalon's mechanism involves cumulative telomerase activation over the full 10–20 day period; a single missed dose does not reset the effect, though it may slightly reduce the overall magnitude of telomere lengthening observed in endpoint measurements. If multiple doses are missed (three or more), consider restarting the cycle after a washout period to maintain protocol integrity.

What If My Reconstituted NAD+ Develops Cloudiness After One Week?

Discard the vial immediately—cloudiness indicates bacterial growth, oxidation, or peptide aggregation. NAD+ solutions should remain clear and colorless throughout the 28-day refrigerated storage window. Cloudiness suggests either contamination during reconstitution, repeated temperature excursions above 8°C, or use of non-bacteriostatic water. Do not inject cloudy peptide solutions; the risk of injection site reaction or systemic immune response outweighs any potential benefit from the degraded compound.

What If I Want to Extend Epithalon Cycles Beyond 20 Days?

No peer-reviewed evidence supports continuous Epithalon administration beyond 20 days per cycle. Published protocols by Khavinson used 10–20 day cycles specifically to avoid receptor desensitization or diminished telomerase response. Extending cycles to 30+ days may not increase benefit and could theoretically reduce the magnitude of effect observed in subsequent cycles. If longer intervention periods are desired, consider two 10-day cycles separated by a 4-week washout rather than a single extended cycle.

What If I Experience Injection Site Redness or Swelling?

Rotate injection sites and verify proper reconstitution technique. Subcutaneous injections of peptides should produce minimal local reaction—persistent redness, swelling, or warmth suggests either an immune response to the peptide, contamination of the solution, or injection technique error (injecting too quickly, using a dull needle, or failing to allow alcohol swabs to dry fully before injection). If symptoms persist beyond 48 hours or spread beyond the injection site, discontinue use and consult the supervising investigator or licensed prescriber.

The Sobering Truth About NAD+ Epithalon Stack Protocols

Here's the honest answer: most NAD+ Epithalon stack protocols are based on theoretical synergy, not clinical trial data demonstrating additive or synergistic effects. NAD+ has robust evidence supporting mitochondrial function and sirtuin activation. Epithalon has published Russian research showing telomerase upregulation and lifespan extension in rodent models. But peer-reviewed trials specifically testing the combination—measuring whether stacking produces outcomes superior to either compound alone—are essentially non-existent in Western scientific literature.

The longevity research community operates on mechanistic reasoning: NAD+ supports energy metabolism and DNA repair, Epithalon targets telomere maintenance and circadian function, therefore combining them should address multiple hallmarks of aging simultaneously. That reasoning is plausible, but plausibility is not evidence. Researchers adopting these protocols are conducting exploratory investigations, not replicating validated interventions. The dosing schedules, cycle lengths, and washout periods are extrapolated from single-compound studies, not optimized through dose-response trials of the stack itself.

This doesn't mean the protocols are without value—early-stage research requires hypothesis-driven experimentation. But investigators should approach NAD+ Epithalon stacks with clear endpoints, baseline measurements, and realistic expectations. Telomere length analysis, biomarkers of mitochondrial function (NAD+/NADH ratios, ATP production), and circadian rhythm assessments (melatonin profiles, cortisol rhythms) provide objective data to evaluate whether the intervention produced measurable effects. Subjective reports of